Literature DB >> 15787732

World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays.

J Saldanha1, A Heath, C Aberham, J Albrecht, G Gentili, M Gessner, G Pisani.   

Abstract

BACKGROUND AND OBJECTIVES: A collaborative study was undertaken to establish a replacement for the current (1st) World Health Organization (WHO) hepatitis C virus (HCV) International Standard, 96/790.
MATERIALS AND METHODS: Both the 1(st) International Standard and the replacement standard were prepared from the same starting material by diluting a high titre genotype 1a HCV isolate in pooled, human plasma. The only difference was that each standard was lyophilized in two, separate lyophilisation runs but under the same conditions.
RESULTS: In the study to establish the 1st International Standard, no significant difference in potency was found between the material eventually designated as the 1st International Standard and that now selected as the 2nd International Standard. The present study also showed no significant differences between the materials stored at -20 degrees C and no evidence of degradation over 5 years.
CONCLUSIONS: Material 96/798 was established as the 2nd HCV International Standard and assigned the same unitage as the 1st International Standard, i.e. 10(5) IU/ml (50,000 IU/vial).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15787732     DOI: 10.1111/j.1423-0410.2005.00606.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  15 in total

1.  Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.

Authors:  F Wiesmann; G Naeth; C Sarrazin; A Berger; R Kaiser; R Ehret; H Knechten; P Braun
Journal:  Med Microbiol Immunol       Date:  2014-11-15       Impact factor: 3.402

Review 2.  International standards and reference materials for quantitative molecular infectious disease testing.

Authors:  Roberta M Madej; Jack Davis; Marcia J Holden; Stan Kwang; Emmanuel Labourier; George J Schneider
Journal:  J Mol Diagn       Date:  2010-01-14       Impact factor: 5.568

Review 3.  Standardization of Nucleic Acid Tests: the Approach of the World Health Organization.

Authors:  S A Baylis; P Wallace; E McCulloch; H G M Niesters; C M Nübling
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

Review 4.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay.

Authors:  Michael T Pyne; Eric Q Konnick; Amit Phansalkar; David R Hillyard
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

6.  Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study.

Authors:  G Colucci; J Ferguson; C Harkleroad; S Lee; D Romo; S Soviero; J Thompson; M Velez; A Wang; Y Miyahara; S Young; C Sarrazin
Journal:  J Clin Microbiol       Date:  2007-09-26       Impact factor: 5.948

7.  Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification.

Authors:  Johannes Vermehren; Annika Kau; Barbara C Gärtner; Reinhild Göbel; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

8.  RNase-resistant virus-like particles containing long chimeric RNA sequences produced by two-plasmid coexpression system.

Authors:  Yuxiang Wei; Changmei Yang; Baojun Wei; Jie Huang; Lunan Wang; Shuang Meng; Rui Zhang; Jinming Li
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

Review 9.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

Review 10.  Standardization of NAT for Blood-Borne Pathogens.

Authors:  Sally A Baylis; Michael Chudy; C Micha Nübling
Journal:  Transfus Med Hemother       Date:  2015-07-01       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.